Portfolio

CLOSE ×
Arktus Therapeutics Co., Ltd.
Company Profile

iPS cell technology×Bio-3D printing technology Arktus Therapeutics has developed the world's first treatment method by integrating the pioneering iPS cell technology from Kyoto University with Saga University's Bio-3D printing technology. We've achieved the regeneration of joint cartilage that maintains complex curved surfaces, enabling the restoration of the knee joint's natural shape and function.

Related JST Programs

A-STEP (Adaptable and Seamless Technology Transfer Program through Target-Driven R&D)

Comprehensive Support Programs for Creation of Regional Innovation

URL

https://arktustx.com/en

SDGs
CLOSE ×
DigitalArchi Co., Ltd.
Company Profile

DigitalArchi　Using our independently developed large 3D printer,We create construction resin concrete forms, interior and exterior panels, etc. We manufacture and sell building materials made from recycled plastic, realizing a truly sustainable society through the optimization of resources.

Related JST Programs

The Program on Open Innovation Platform for Industry-academia Co-creation (COI-NEXT)

Center of Innovation (COI) Program

URL

https://www.digital-archi.com/en

SDGs
CLOSE ×
TopoLogic Inc.
Company Profile

TopoLogic is a QX (quantum transformation) startup from the University of Tokyo that aims to socially implement materials based on quantum science. They aim to apply the knowledge of new materials obtained in the field of condensed matter physics to devices, products, and services.

Related JST Programs

CREST (Core Research for Evolutional Science and Technology)

JST-Mirai program

URL

https://www.topologic.jp/

SDGs
CLOSE ×
BioPhenolics Inc.
Company Profile

BioPhenolics Inc., is a startup company founded in February 2023 based on promising results from the University of Tsukuba. They are aiming to achieve carbon neutrality through the production of bio-aromatic compounds by precision fermentation of microorganisms. Biomanufacturing, the production of chemical compounds from biomass, is attracting attention as a technology with low environmental impact. They are developing technology to industrially produce bio-based aromatic compounds through the fermentation of "smart cells", microorganisms genetically modified to efficiently produce chemical compounds. By establishing a system capable of developing integrated refining and mass production technologies in addition to the development of smart cells, they aim to clear the current issues of mass production and economic efficiency, and to realize the supply of bio-chemicals as an alternative to petrochemicals by 2030.

Related JST Programs

ALCA(the Advanced Low Carbon Technology Research and Development Program)

CREST (Core Research for Evolutional Science and Technology)

SCORE (Program of Start-up incubaition from COre REsearch)

URL

https://bio-phenolics.com/

SDGs
CLOSE ×
Restore Vision Inc.
Company Profile

Restore Vision Inc. is a startup company founded in November 2016, based on promising results of a joint research between associate professor Toshihide Kurihara at Keio University School of Medicine and professor Hideki Kandori at Nagoya Institute of Technology to develop a visual restoration gene therapy for blindness caused by retinal disorders, using a clinical application of optogenetics technology. RV-001 is the lead gene therapy product in the pipeline, using adeno-associated virus (AAV) vectors with the unique functional gene coding ‘Chimeric Rhodopsin’ which is a protein-based optical sensor. It is a treatment that can restore vision in patients blinded by photoreceptor loss. They take a simple and minimally invasive approach, intravitreal injection, to deliver our therapeutic gene that will express chimeric rhodopsin in the remaining interneurons, enabling the patient to see again. Restore Vision’s mission is to deliver therapies at light speed to patients waiting for an effective treatment and end blindness by making cutting-edge gene therapy technology available to all.

Related JST Programs

CREST (Core Research for Evolutional Science and Technology)

URL

https://restore-vis.com/en/

SDGs
CLOSE ×
C4U CORPORATION
Company Profile

C4U is founded as a life science start-up company based on IPRs that are secured by Osaka University. They have an exclusive license from Osaka University in terms of a core technology related to proprietary gene editing technologies so-called CRISPR-Cas3 that is characterized by its unprecedentedly high target sequence specificity (giving a safety profile in a medical term) and large scale edition (providing an efficient knock-out of a target gene). The technology is attracting attention as a promising genome editing technology that can compete with CRISPR-Cas9, which is being studied in the world and is still under certain patent disputes. C4U is developing novel gene therapies for genetic diseases utilizing CRISPR-Cas3 technology and developing this technology as a platform technology.

Related JST Programs

OPERA (Program on Open Innovation Platform with Enterprises, Research Institute and Academia)

URL

https://www.crispr4u.jp/en/

SDGs
CLOSE ×
FerroptoCure Inc,
Company Profile

FerroptoCure Inc, is a company that develops next-generation anticancer drugs and other therapeutic drugs based on scientific evidence. Its pipeline focuses on ferroptosis. Ferroptosis is an iron-dependent cell death induced by oxidative stress and is revealed to be involved in the occurrence and progression of various diseases such as cancer, neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, etc.), and hepatitis (NASH). In particular, recent studies have shown that controlling ferroptosis is strongly involved in the occurrence, progression, and metastasis of cancers. It aims to deliver new anticancer drugs to cancer patients by developing the technology to control ferroptosis.

Related JST Programs

CREST (Core Research for Evolutional Science and Technology)

SCORE (Program of Start-up incubaition from COre REsearch)

URL

https://ferroptocure.com/en/

SDGs
CLOSE ×
Alpha Fusion Inc.
Company Profile

Alpha Fusion Inc. is a company that focuses on Astatine(At-211)-based radiopharmaceuticals. In recent years, therapeutics based on alpha-emitting radioisotopes have attracted increasing attention. Targeted Alpha Therapy (TAT) is based on the coupling of alpha particle emitting radioisotopes to tumour selective various ligands as a carrier. Alpha particles have high energy and a short path length in human tissue. Consequently, the use of alpha emitters allows the specific targeting and killing of individual malignant cells while minimizing the toxicity to surrounding healthy tissue, leading to safe and effective treatments. Alpha Fusion aims to unleash the therapeutic potential of Astatine (At-211) and develop new cancer treatments through R&D as well as business development efforts to realize this innovative modality.

Related JST Programs

OPERA(Program on Open Innovation Platform with Enterprises, Research Institute and Academia)

URL

https://alpha-fusion.com/

SDGs
CLOSE ×
LQUOM, Inc.
Company Profile

LQUOM is a deep-tech startup from Yokohama National University. LQUOM develops long-distance quantum communication technology, including a quantum repeater system, to realize the quantum internet. A significant advantage of the quantum internet is unconditionally (i.e., information-theoretically) secure communication. The current cryptography depends on computational security, which can be broken once a quantum computer has extremely high computational performance. Before the era of quantum computation, we need to realize the quantum internet. Currently, long-distance quantum communication is severely limited because quantum information in a single photon is mostly lost in a long optical fiber. Elongation of the unconditionally secure quantum communication requires “quantum repeaters” between two distant sites. LQUOM has core technologies for quantum repeaters and continues the development of quantum repeater systems to realize the quantum internet.

Related JST Programs

START (Program for Creating STart ups from Advanced Research and Technology)

URL

https://lquom.com/en/

SDGs
CLOSE ×
TamaBio Inc.
Company Profile

TamaBio's synthetic artificial biological membrane develops newborn cells and capillaries on the surface and integrates with human tissues.
It has obtained regulatory approval for artificial dura mater and artificial pericardium, and clinical use has reached 1000 cases, and the treatment results are far better than existing technologies.
We have obtained our own patents in Japan, the United States, the People's Republic of China, etc. Entering the regulatory approval process at the US Food and Drug Administration.
In the future, we will sequentially develop patches for heart repair, artificial blood vessels, gastrointestinal wrapping, trigeminal neuralgia treatment devices, artificial heart valves, etc.
We will expand clinical use to the world such as the US and China, and contribute to the advancement of treatment technology.

Related JST Programs

Project to Develop "Innovative Seeds"

URL

-

SDGs
CLOSE ×
QunaSys Inc.
Company Profile

QunaSys was established based on the reserch from JST's program PRESTO (Precursory Research for Embryonic Science and Technology) .
QunaSys is aiming to accelerate the development of the practical application of quantum technology.
QunaSys is a startup company that aims to utilize quantum computers in society by conducting research on algorithms that make good use of quantum computers and developing software that makes it easy for users.

Related JST Programs

PRESTO (Precursory Research for Embryonic Science and Technology)

URL

https://en.qunasys.com/

SDGs
CLOSE ×
SoLARIS Inc.
Company Profile

SoLARIS Inc. (hereinafter referred to as "Solaris") was founded in 2017 and is a university-launched venture company based on the research results of the Biomechanics Laboratory at Chuo University.
We aim to commercialize the results of our cutting-edge research on soft robots that learn from the functions of living things and organisms.
With high-powered, lightweight and flexible pneumatic artificial muscles as its core technology, Solaris has unique technologies that are unparalleled in the world, such as the Peristaltic-type pump robots with the ability to mix and carry, and the earthworm-type robots that move like earthworm through complex pipes.
We will promote the commercialization of the earthworm-type robots for visualizing and inspecting complex narrow pipes, and the Peristaltic-type pump robots for mixing and conveying solid-liquid multiphase fluids with excellent explosion-proof performance, and we aim to commercialize soft robots that are highly desired in many industries, such as inspection and cleaning of infrastructure, factories, plants, and building piping, and manpower saving at chemical and food production sites and civil engineering and construction sites.

Related JST Programs

Industry-Academia Collaborative R＆D Programs / ex-Comprehensive Support Programs for Creation of Regional Innovation "Research for Promoting Technological Seeds".

URL

https://solaris-inc.com/

SDGs
CLOSE ×
CoreTissue BioEngineering Inc.
Company Profile

Our first target is an implantable medical device for treatment of the rupture of the ACL. Our concept is to make a medical device with animal tendon. Our tissue source is tendon from cow’s legs which is strong enough as an artificial ligament.

To prevent allergic reaction or graft rejection, we remove cells from the tissue. The tendon is freeze-dried and sterilized after removing the cells. The device is an off-the-shelf product that can be stocked in hospitals to be available at any time.

We utilize the following two key technologies invented by Prof. Kiyotaka Iwasaki. Ph.D., Waseda University:
1. Decellularization technology radiating microwave to the tissue and washing cell components with the palatized perfusion of detergent (MAPP method)
2. Lyophilization and sterilization technology maintaining the mechanical property of the artificial ligament and providing recovery to supple condition easily once immerse to the saline solution

These technologies could make it possible to develop the artificial ligament with biocompatibility and mechanical strength as the artificial ligament.

Related JST Programs

A-STEP (Adaptable and Seamless Technology Transfer Program through Target-Driven R&D)

START (Program for Creating STart ups from Advanced Research and Technology)

URL

https://www.coretissue.com/?lang=en

SDGs
CLOSE ×
SONIRE Therapeutics Inc.
Company Profile

SONIRE Therapeutics (hereinafter, "SONIRE")] is a company that develops high-intensity focused ultrasound (HIFU) therapy systems by utilizing the technology and know-how built up at Tokyo Women's Medical University, Tohoku University, and Tokyo Medical University.
SONIREʼs vision is to bring a new future to cancer patients through acoustic engineering (ultrasound). The company is promoting development to treat pancreatic cancer which is an especially intractable cancer.

Related JST Programs

Center of Innovation (COI) Program

URL

https://en.sonire-therapeutics.com/

SDGs
CLOSE ×
bitBiome, Inc.
Company Profile

bitBiome was founded in November 2018 as a spinout from Waseda University. Its proprietary bit-MAP® platform is the world’s only single-cell genome analysis technology specific to microorganisms. Using this platform, rapid, comprehensive, and accurate analysis of unknown microbes can be achieved, without requiring the isolation and cultivation of the cells or complicated data processing typically required in conventional microbiome research. bitBiome provides this technology to academic and corporate partners, mainly in the pharmaceutical and agricultural fields, for next-generation microbiome analysis to unlock the potential of microbes.

Related JST Programs

PRESTO (Precursory Research for Embryonic Science and Technology)

URL

https://www.bitbiome.co.jp/en/

SDGs
CLOSE ×
BionicM Inc.
Company Profile

BionicM is a startup from the University of Tokyo that conducts R&D and commercialization of robotic prostheses.
Dr. Sun, the founder and CEO, also uses prostheses himself. He decided to start a business based on his engineering experience at Sony and robotics engineering research at the University of Tokyo.It was established in December 2018.
Utilizing cutting-edge technology based on robotics engineering research at the University of Tokyo, the BionicM prosthesis solves the problems of conventional prostheses and creates a compact, lightweight, highly functional prosthesis that allows natural movement.

Related JST Programs

START (Program for Creating STart ups from Advanced Research and Technology)

URL

http://www.bionicm.com/en/top/

SDGs
CLOSE ×
PROVIGATE Inc.
Company Profile

Provigate, Inc. is a company that develops home-use glucose monitoring systems. The company was founded in 2015 based on unique sensing technologies invented by Dr. Sakata of The University of Tokyo. The company develops the world's first minimum or non-invasive glucose monitoring systems for diabetic and pre-diabetic people to improve their glycemic control in daily life. Provigate is based in Tokyo, Japan.

Related JST Programs

CREST (Core Research for Evolutional Science and Technology)

JST-SENTAN Program(Development of Advanced Measurement and Analysis Systems)

JST-Mirai Program

URL

http://www.provigate.com/en/

SDGs
CLOSE ×
Rege Nephro Co.,Ltd.
Company Profile

RegeNephro is a biotech venture established in September 2019 that utilizes the research achievements by Prof. Kenji Osafune, Center for iPS Cell Research and Application (CiRA), Kyoto University, who developed technology for the efficient generation and expansion of nephron progenitor cells derived from iPS cells (iPSC-NPCs). Using iPSC-NPCs, RegeNephro is developing regenerative medicine for chronic kidney disease (CKD) to improve patients’ quality of life (QOL) by preventing the progression of CKD and transition to dialysis therapy.

Related JST Programs

PRESTO (Precursory Research for Embryonic Science and Technology)

Research Center Network for Realization of Regenerative Medicine

URL

https://www.regenephro.co.jp/

SDGs
CLOSE ×
KAICO LTD.
Company Profile

KAICO Ltd., founded in April 2018, is a startup that began at Kyushu University. Rather than silk, our unique strain of silkworms produce medical-use proteins in high yields and top quality. We can produce those proteins for companies and researchers for use in medicines and vaccines. Our startup builds upon more than a century of silkworm breeding and research conducted at Kyushu University. We have unparalleled knowledge of both how to create recombinant proteins, which are of central importance to modern medicine, and also how to rear silkworms. We are confident that our technology will be essential in combating newly emerging viruses.

Related JST Programs

START (Program for Creating STart ups from Advanced Research and Technology)

URL

http://www.kaicoltd.jp/home/english-home/

SDGs
CLOSE ×
Algal Bio Co., Ltd.
Company Profile

Algal Bio Co., Ltd. was established in March 2018 based on the results of research on advanced breeding for algae by Professor Emeritus Shigeyuki Kawano of the University of Tokyo.
Algal Bio Co., Ltd. aims to provide safe and secure food materials derived from natural products, functional ingredients such as food and cosmetics, food additives, pharmaceutical raw materials, biofuels, etc. by utilizing microalgae to meet customer needs.

Related JST Programs

CREST (Core Research for Evolutional Science and Technology)

START (Program for Creating STart ups from Advanced Research and Technology)

URL

https://algalbio.co.jp/

SDGs
CLOSE ×
ActualEyes Inc.
Company Profile

ActualEyes Inc. is a spin-off venture company from Doshisha University, established on May 1st, 2018. ActualEyes Inc. aims to research, develop and commercialize 1) eye drops to treat Fuchs endothelial corneal dystrophy (FECD) and 2) cell therapy for corneal endothelial treatment, based upon the research seeds of Professor Noriko Koizumi and Associate Professor Naoki Okumura of Doshisha University, who are clinical scientists in the field of ophthalmology.

Related JST Programs

Industry-Academia Collaborative R＆D Programs / ex-Comprehensive Support Programs for Creation of Regional Innovation "Research for Promoting Technological Seeds".

A-STEP (Adaptable and Seamless Technology Transfer Program through Target-Driven R&D)

URL

https://www.actualeyes.co.jp/

SDGs
CLOSE ×
EditForce Inc.
Company Profile

The business of EditForce Inc. is based on two technologies using PPR proteins - its unique genome (DNA) editing and its world-first RNA editing technologies. This business contributes to the development of the global bio industry. The strengths of the company's basic technologies are that it is possible to theoretically design protein molecules that bind to desired DNA or RNA sequences. The company hopes that creating applications which can control genes and gene expressions in various stages will make it possible to expand to various industries (e.g., medical care, agriculture and material production).

Related JST Programs

PRESTO (Precursory Research for Embryonic Science and Technology)

A-STEP (Adaptable and Seamless Technology Transfer Program through Target-Driven R&D)

OPERA(Program on Open Innovation Platform with Enterprises, Research Institute and Academia)

URL

https://www.editforce.co.jp/en/

SDGs
CLOSE ×
Craif, Inc. (former Icaria Inc.)
Company Profile

Craif’s core technology is fabricating nanomaterials and applying them to biological use. We developed a device to extract biomolecules from body fluids such as urine. This device consists of micro-fluid with ZnO nanowire, which can efficiently extract exosomes (>99%) and miRNA (>1300 species).
Currently, Craif is working on developing a urinal test for early cancer detection. The company utilizes a machine learning approach to analyze miRNA profiles collected comprehensively from urine samples.

Related JST Programs

PRESTO (Precursory Research for Embryonic Science and Technology)

URL

https://www.craif.com/en/

SDGs
CLOSE ×
Himuka AM Pharma Corp.
Company Profile

Himuka AM Pharma Corp. is a startup originating from the University of Miyazaki with headquarters in Miyazaki. Himuka AM is focused on the development of the bioactive peptide adrenomedullin (AM) which was discovered at the University of Miyazaki (formerly Miyazaki Medical College). Clinical study at the University of Miyazaki suggests that AM has a remarkable healing (regeneration) effect on intestinal mucosa for inflammatory bowel disease. Based on this research, Himuka AM is developing new drugs to provide treatment with an approach that is completely different to approved drugs and contribute to the resolution of Unmet Medical Needs.

Related JST Programs

Industry-Academia Collaborative R＆D Programs / ex-Comprehensive Support Programs for Creation of Regional Innovation "Research for Promoting Technological Seeds".

START (Program for Creating STart ups from Advanced Research and Technology)

URL

https://www.himuka-am.com/

SDGs
CLOSE ×
THINKCYTE INC.
Company Profile

ThinkCyte has built the Ghost Cytometry technology, the world’s first high-throughput image-based cell sorting system by integrating advanced imaging, machine learning and microfluidics technologies. It enables researchers to identify cells based on their high content phenotypes (i.e. fluorescence and phase images) and isolate the target cells at high throughput, even without any labels. This innovative approach brings high-throughput, content-rich analysis and sorting on a single cell level to disciplines such as phenotypic drug screening and cell therapy.

Related JST Programs

PRESTO (Precursory Research for Embryonic Science and Technology)

URL

https://thinkcyte.com/

SDGs
CLOSE ×
Photo electron Soul Inc.
Company Profile

Photo electron Soul develops, manufactures and sells next generation electron beam generation systems. Photo electron Soul offers products based on photocathode technologies cultivated over more than 30 years at Nagoya University.
This company is currently targeting semiconductor inspection equipment. Its systems contribute significantly to the major issue of inspection time.
In the future, with this business as its starting point, Photo electron Soul will also aim to develop its systems for other uses and to reform industrial use electron beams.

Related JST Programs

JST-SENTAN Program(Development of Advanced Measurement and Analysis Systems)

URL

http://photoelectronsoul.com/english/

SDGs
CLOSE ×
KORTUC Inc.
Company Profile

KORTUC Inc is developing a radiation sensitizer that will greatly improve radiotherapy. The therapy has benefited over 1,000 Japanese patients, and the first GCP based Phase 1 trial in the Royal Marsden Hospital (U.K.) confirmed safety in 2018. A following Phase 2 trial aims to prove superior efficacy for breast cancer, which will lead to regulatory approval for our product globally for any type of solid tumor. Our potential market is huge, containing all cancer patients who will receive radiation therapy (approx. 12 million patients annually) around the world.

Related JST Programs

Industry-Academia Collaborative R＆D Programs / ex-Comprehensive Support Programs for Creation of Regional Innovation "Research for Promoting Technological Seeds".

URL

https://kortuc.com/

SDGs
CLOSE ×
TOKIWA-Bio Inc.
Company Profile

TOKIWA-Bio Inc. develops, manufactures and sells gene therapy drugs and regenerative medicine related products and research reagents utilizing stealth RNA vector.

Related JST Programs

Industry-Academia Collaborative R＆D Programs / ex-Comprehensive Support Programs for Creation of Regional Innovation "Research for Promoting Technological Seeds".

START (Program for Creating STart ups from Advanced Research and Technology)

URL

http://www.tokiwa-bio.com/

SDGs
CLOSE ×
Rebirthel Co., Ltd.
Company Profile

Rebirthel Co., Ltd. aims to realize cell-based therapies against cancer or other immune-related diseases by using “off-the-shelf T cells” that are regenerated from pluripotent stem cells, such as iPS cells or ES cells. The strategy is based on methods developed by Dr. Hiroshi Kawamoto (Kyoto University).
Rebirthel thus opens the way to a future when patients go to hospital to receive transfusion of T cells to treat their disease.

Related JST Programs

CREST (Core Research for Evolutional Science and Technology)

URL

https://rebirthel.com/en/

SDGs
CLOSE ×
RegCell Co., Ltd
Company Profile

RegCell aims to generate novel therapeutic technologies, especially using Regulatory T cells (Treg), and save patients who suffer from autoimmune diseases. Its original induced Treg cells, “ULTRA-iTreg” cells, are functionally stable and effective cell therapy product. RegCell is proactively developing cells for inflammatory diseases.

Related JST Programs

CREST (Core Research for Evolutional Science and Technology)

URL

http://regcell.jp/home_en

SDGs
CLOSE ×
Karydo TherapeutiX, Inc.
Company Profile

Karydo is a science-first company aiming to establish “Virtual Live Clinics (VLC)”. VLC is a business platform proposed by our scientific founder, Dr. Thomas N. Sato, in 2013. It is the ultimate platform to provide personalized medical/health solutions to everyone at anytime and anywhere. At Karydo, top-notch scientists discover breakthrough concepts and technologies in the areas of biomedical science, mathematics, data science, computer science, engineering and other related disciplines to realize VLC.

Related JST Programs

ERATO(Exploratory Research for Advanced Technology)

URL

http://karydo-tx.com/home-english/

SDGs
CLOSE ×
Future Ink Corporation
Company Profile

Future Ink Corporation (FIC) started business by developing, manufacturing and selling low temperature sintered silver nanoparticle inks for printed electronics. Based on this technology, FIC is now actively working on the development of sensor devices manufactured by printing.
FIC has commercialized a film-type high sensitivity bed sensor that can "casually" monitor the heartbeat, breathing and depth of sleep of sleeping people. Currently, FIC is promoting demonstration and application development in the field of nursing care and medical care toward the commercialization of this bed sensor.

Related JST Programs

START (Program for Creating STart ups from Advanced Research and Technology)

URL

http://www.futureink.co.jp/eng/

SDGs
CLOSE ×
GORYO Chemical, Inc.
Company Profile

Goryo Chemical creates innovative fluorescent probes through licensing and in-house value addition by expanding applications in cell biology and expediently bringing them to researchers in academia, small biotech as well as large pharmaceutical companies.

Related JST Programs

Strategic Basic Research Programs：PRESTO (Precursory Research for Embryonic Science and Technology), CREST (Core Research for Evolutional Science and Technology))

URL

https://goryochemical.com/en/

SDGs
CLOSE ×
Kyulux, Inc.
Company Profile

Kyulux was established in Japan in 2015 to develop next generation materials for OLED displays and lighting. Based on exclusively-licensed technology from Kyushu University and Harvard University, Kyulux develops Hyperfluorescence/TADF emitting technology that will enable cost-effective, durable and efficient OLEDs that do not rely on rare metal. Kyulux aims to commercialize the world's first Hyperfluorescence technology.

Related JST Programs

CREST (Core Research for Evolutional Science and Technology)

URL

https://www.kyulux.com/

SDGs
CLOSE ×
Medicinal Chemistry Pharmaceutical, Co., Ltd. (MCP)
Company Profile

Medicinal Chemistry Pharmaceutical has both synthetic and analytical technologies for glycoconjugates. The company possesses extensive biochemical experiment technologies, meeting all glycan-related needs while aiming to discover drugs with glycopeptide and anti-glycopeptide antibodies. It does this by making full use of four core technologies: 1) the GlycoBlotting method, 2) glycopeptide synthesis, 3) biomimetic nanoparticle preparation technology and 4) glycopeptide arrays. The company will continue to help with the development of life sciences and contribute to the healthy lives of people by providing the standard for glycoscience.

Related JST Programs

JST-SENTAN Program(Development of Advanced Measurement and Analysis Systems)

URL

https://soyaku.co.jp/english/

SDGs
CLOSE ×
Axelspace Corporation
Company Profile

Axelspace is a start-up company in the space business utilizing artificial microsatellites. It has developed and operated five commercial satellites, including the world’s first private commercial microsatellite. The basis is original microsatellite technology created from scratch at the University of Tokyo and the Tokyo Institute of Technology, giving Axelspace satellites unrivaled cost competitiveness worldwide. Axelspace is developing a business utilizing satellite image data with orbital infrastructure in this new era created by microsatellites.

Related JST Programs

Project to Develop "Innovative Seeds"

Science and Engineering Entrepreneurship Development Program for Vigorous Researchers

URL

https://www.axelspace.com/en/

SDGs
CLOSE ×
SleepWell Co., Ltd.
Company Profile

SleepWell provides scientific sleep assessment systems, including a user-friendly single-channel electroencephalograph and data-driven sleep analysis system. Both have received medical device approval from the Japanese regulatory authority, PMDA. Although it is a sleep monitoring system based on world-standard EEG, the development concept is completely different. SleepScope enables easy and natural sleep measurement at home instead of a complicated attended inspection that needs to be monitored in a sleep lab. Easier measurement has allowed SleepWell to collect a lot of data and to develop a data-driven analysis system. Such daily sleep assessments are clinically beneficial and have been appreciated by doctors in the departments of gastroenterology and diabetes metabolism as well as sleep medicine physicians. The challenge of contributing to people's health through sleep science will expand from Japan to the world.

Related JST Programs

Project to Develop "Innovative Seeds"

Science and Engineering Entrepreneurship Development Program for Vigorous Researchers

URL

https://sleepwell.co.jp/

SDGs

IPO

CLOSE ×
Cyfuse Biomedical K.K.
Company Profile

Cyfuse Biomedical is a start-up company aiming to meet needs not fulfilled by existing treatments, utilizing its unique technology to create 3D tissue.
Cyfuse has developed innovative cell products in the field of regenerative medicine and cell medicine by using original Bio 3D printers that enable scaffold-free 3D tissue fabrication.

Related JST Programs

Industry-Academia Collaborative R＆D Programs / ex-Comprehensive Support Programs for Creation of Regional Innovation "Practical Application Research".

A-STEP (Adaptable and Seamless Technology Transfer Program through Target-Driven R&D)

URL

https://www.cyfusebio.com/en/

SDGs
CLOSE ×
FunPep Co., Ltd.
Company Profile

FunPep is a bio start-up company that puts results of research into functional peptides at the Graduate School of Medicine in Osaka University into practical use. In our main pharmaceutical field, we are conducting research and development on the skin ulcer therapeutic agent, SR-0379, and antibody-inducing peptides.
SR-0379 is expected to be a unique wound therapeutic agent with both antibacterial activity and wound healing promotion effect. Also, antibody-inducing peptides with low manufacturing costs are expected to become affordable alternative pharmaceutical products to antibody drugs.

Related JST Programs

Industry-Academia Collaborative R＆D Programs / ex-Comprehensive Support Programs for Creation of Regional Innovation "Research for Promoting Technological Seeds".

URL

https://www.funpep.co.jp/en/

SDGs

Portfolio

Portfolio

Arktus Therapeutics Co., Ltd.

DigitalArchi Co., Ltd.

TopoLogic Inc.

BioPhenolics Inc.

Restore Vision Inc.

C4U CORPORATION

FerroptoCure Inc,

Alpha Fusion Inc.

LQUOM, Inc.

TamaBio Inc.

QunaSys Inc.

SoLARIS Inc.

CoreTissue BioEngineering Inc.

SONIRE Therapeutics Inc.

bitBiome, Inc.

BionicM Inc.

PROVIGATE Inc.

Rege Nephro Co.,Ltd.

KAICO LTD.

Algal Bio Co., Ltd.

ActualEyes Inc.

EditForce Inc.

Craif, Inc. (former Icaria Inc.)

Himuka AM Pharma Corp.

THINKCYTE INC.

Photo electron Soul Inc.

KORTUC Inc.

TOKIWA-Bio Inc.

Rebirthel Co., Ltd.

RegCell Co., Ltd

Karydo TherapeutiX, Inc.

Future Ink Corporation

GORYO Chemical, Inc.

Kyulux, Inc.

Medicinal Chemistry Pharmaceutical, Co., Ltd. (MCP)

Axelspace Corporation

SleepWell Co., Ltd.

IPO

Cyfuse Biomedical K.K.

FunPep Co., Ltd.

Exited

TELEXISTENCE Inc.

Xenoma Inc.

Medical Data Card, Inc.

Robotic Biology Institute Inc.

Portfolio